#United States #Indianapolis #biotechnology #Eli Lilly #Health Care

Eli Lilly's Participation in the Upcoming Health Care Conference

Eli Lilly and Company, a leader in the pharmaceutical industry, has announced its participation in the highly anticipated TD Cowen's 45th Annual Health Care Conference scheduled for March 4, 2025. The event will provide a platform for industry leaders to discuss the latest advancements in healthcare, and Eli Lilly is poised to make a significant contribution to the dialogue.

Scheduled to speak at the event is Jake Van Naarden, the executive vice president and president of Lilly Oncology. He will engage in a candid fireside chat at 1:50 PM Eastern time, where he will likely shed light on Eli Lilly's innovative projects and its ongoing commitment to transforming healthcare. This conference presents an excellent opportunity for attendees to gain insights directly from one of the prominent figures in the oncology field.

In addition to the live discussion, the presentation will be accessible to a broader audience via a live audio webcast, which can be found on the Webcasts & Presentations section of Lilly's investor website. For those unable to attend, a replay of the presentation will be available for approximately 90 days. This ensures that the valuable information shared during the conference reaches a wide audience, allowing for greater engagement with the public and stakeholders.

About Eli Lilly

Eli Lilly and Company has a rich history as a medicine company dedicated to turning scientific advancements into healing solutions that enhance lives globally. For nearly 150 years, Lilly has been at the forefront of medical innovation, helping millions worldwide with its transformative medicines. The company harnesses the power of biotechnology, chemistry, and genetic medicine to confront some of the most pressing health challenges of our time.

Lilly is particularly focused on several critical areas, including:

• - Revolutionizing diabetes care: Addressing one of the most common chronic diseases, Lilly continually evolves its strategies to manage diabetes effectively.
• - Tackling obesity: The company is committed to providing solutions that not only treat obesity but also mitigate its long-term health implications.
• - Advancing Alzheimer's research: Lilly plays a vital role in exploring new treatments for Alzheimer's, striving to redefine care for this challenging condition.
• - Addressing immune system disorders: The company’s work in this field aims to alleviate some of the most debilitating immune conditions.
• - Transforming cancer treatment: Eli Lilly is innovating ways to turn complex cancer cases into treatable realities, thus improving survival rates and quality of life for patients.

Each step Lilly takes towards a healthier world is driven by a singular motivation: making life better for millions. The company emphasizes the importance of diversity in clinical trials and is committed to ensuring its medicines remain accessible and affordable for all.

To explore more about Eli Lilly and follow its ongoing efforts in healthcare innovation, visit Lilly.com and Lilly.com/news, or connect with them on their social media platforms, including Facebook, Instagram, and LinkedIn.

In conclusion, Eli Lilly’s anticipated involvement in TD Cowen's Annual Health Care Conference underscores its ongoing dedication to pioneering healthcare solutions and engaging with the broader community. As the event approaches, stakeholders and interested parties should stay tuned for insights from one of the leading voices in the pharmaceutical industry, along with crucial updates on the company's strategic initiatives and commitments to global health challenges.